Abstract
Recently emerging evidence has shown that epigenetic mechanisms are involved in initiation and progression of various diseases, including kidney diseases. In the present article, we review the current data regarding the role of epigenetic modulation in chronic kidney disease (CKD) and kidney fibrosis, including DNA methylation and histone modification. Especially we focused on the role of transcription factors in epigenetic modulation and the possibility of therapeutic target of CKD. We have recently reported that transcription factor Kruppel-like factor 4 (also known as gut-enriched Kruppel-like factor) is expressed in kidney podocytes (visceral epithelial cells) and modulates podocyte phenotype by gene-selective epigenetic control. Targeting transcription factors for epigenetic modification may be a good candidate for remission and regression of CKD. It is necessary for the therapy of CKD with an epigenetic-based approach to investigate organ-, tissue-, or gene-specific treatment methods for reduction of side effects.
Similar content being viewed by others
References
Aoi T, Yae K, Nakagawa M et al (2008) Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321:699–702
Azuma M, Koyama D, Kikuchi J et al (2012) Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB J 26:4264–4274
Bechtel W, McGoohan S, Zeisberg EM et al (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16:544–550
Bonasio R, Tu S, Reinberg D (2010) Molecular signals of epigenetic states. Science 330:612–616
Bostick M, Kim JK, Esteve PO et al (2007) UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317:1760–1764
Cianciolo Cosentino C, Skrypnyk NI, Brilli LL et al (2013) Histone deacetylase inhibitor enhances recovery after AKI. J Am Soc Nephrol 24:943–953
Deelman LE, Decleves AE, Rychak JJ et al (2010) Targeted renal therapies through microbubbles and ultrasound. Adv Drug Deliv Rev 62:1369–1377
Hauser PV, Pippin JW, Kaiser C et al (2010) Novel siRNA delivery system to target podocytes in vivo. PLoS One 5:e9463
Hayashi K, Sasamura H, Nakamura M et al (2014) KLF4-dependent epigenetic remodeling modulates podocyte phenotypes and attenuates proteinuria. J Clin Invest 124:2523–2537
Hervouet E, Vallette FM, Cartron PF (2009) Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. Epigenetics 4:487–499
Ingrosso D, Cimmino A, Perna AF et al (2003) Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 361:1693–1699
Kinugasa F, Noto T, Matsuoka H et al (2010) Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl Immunol 23:18–23
Kottgen A, Pattaro C, Böger CA et al (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42:376–384
Lefevre GM, Patel SR, Kim D et al (2010) Altering a histone H3K4 methylation pathway in glomerular podocytes promotes a chronic disease phenotype. PLoS Genet 6:e1001142
Liu N, He S, Ma L et al (2013) Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One 8:e54001
Maherali N, Ahfeldt T, Rigamonti A et al (2008) A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3:340–345
Mann BS, Johnson JR, Cohen MH et al (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12:1247–1252
Marumo T, Hishikawa K, Yoshikawa M et al (2010) Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 298:F133–F141
Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD et al (2008) Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2–4 chronic kidney disease. Nephrol Dial Transplant 23:2586–2592
Pang M, Kothapally J, Mao H et al (2009) Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297:F996–F1005
Sharif J, Muto M, Takebayashi S et al (2007) The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450:908–912
Shimizu H, Hori Y, Kaname S et al (2010) siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol 21:622–633
Smyth LJ, McKay GJ, Maxwell AP et al (2014) DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease. Epigenetics 9:366–376
Sun G, Reddy MA, Yuan H et al (2010) Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 21:2069–2080
Sun CY, Chang SC, Wu MS (2012) Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 81:640–650
Sun X, Zhang B, Hong X et al (2013) Histone deacetylase inhibitor, sodium butyrate, attenuates gentamicin-induced nephrotoxicity by increasing prohibitin protein expression in rats. Eur J Pharmacol 707:147–154
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676
Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872
Tampe B, Tampe D, Müller CA et al (2014) Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis. J Am Soc Nephrol 25:905–912
Van Beneden K, Geers C, Pauwels M et al (2011) Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol 22:1863–1875
Yang L, Besschetnova TY, Brooks CR et al (2010) Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16:535–543
Zhong Y, Chen EY, Liu R et al (2013) Renoprotective effect of combined inhibition of Angiotensin-converting enzyme and histone deacetylase. J Am Soc Nephrol 24:801–811
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hayashi, K., Itoh, H. Transcription Factors and Epigenetic Modulation: Its Therapeutic Implication in Chronic Kidney Disease. Arch. Immunol. Ther. Exp. 63, 193–196 (2015). https://doi.org/10.1007/s00005-014-0326-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-014-0326-6